Skip to content

BB Biotech AG

🇨🇭XSWX.BIONSwitzerlandHealthcare

CHF 51.10CHFdown -0.10 (-0.2%)ClosedEnd of day4:43 AM

PriceCHF 51.10-0.10 (-0.2%)

Latest anomalies

Negative 1 detected in the last 120 days

  • High: 1
  • Medium: 2
  • Low: 0
  • Volume: a spike above the 20-day average

    Price Medium

  • Net margin: collapsed against the prior period

    Fundamentals High

  • Operating income: crossed zero, from positive to negative

    Fundamentals Medium

View all anomalies

Free with a Finzer account.

Profile

  • Healthcare
  • Biotechnology
  • Switzerland

Identity

Type
Stock
ISIN
CH0038389992
CUSIP
Not reported

Company

Employees
10
Headquarters
Küsnacht, Germany

Market

Shares outstanding
55.1M
Market cap
CHF 2.79B

Highlights

Day rangeCHF 50.90 - CHF 51.60
today's session
52-week rangeCHF 35.65 - CHF 57.00
from 249 sessions
Market cap
CHF 2.79B
EPS LTM
-CHF 8.01
P/E LTM
-6.38calculatedCalculated by Finzer, not reported by the data provider.
Div yield
14.87%calculatedCalculated by Finzer, not reported by the data provider.

Fundamentals (LTM)

Revenue
-CHF 176.15M-152.93%down year on year
Net income
-CHF 438.69M-287.36%down year on year
Gross margin
99.77%-20.75%down year on year
Free cash flow
CHF 435.73M+317.02%up year on year

View all financials

Latest news

News is not sourced for this exchange.

Business summary

BB Biotech AG is a company in the healthcare sector, listed on SIX Swiss Exchange (Switzerland) under the ticker BION. Its market capitalisation is CHF 2.79B, from 55.1M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHF 35.65 and CHF 57.00, and the last close of CHF 51.10 sits 72% of the way up that range. The company is headquartered in Küsnacht, Germany, and employs about 10 people. The same company also trades as BBZA on Xetra, and as BBZA on Frankfurt Stock Exchange.

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.